Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Caladrius Bio (CLBS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,108
  • Shares Outstanding, K 10,382
  • Annual Sales, $ 0 K
  • Annual Income, $ -16,170 K
  • 60-Month Beta 1.59
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.44
  • Number of Estimates 2
  • High Estimate -0.43
  • Low Estimate -0.44
  • Prior Year -0.42
  • Growth Rate Est. (year over year) -4.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.65 +8.30%
on 06/10/19
3.14 -8.56%
on 05/20/19
-0.13 (-4.33%)
since 05/17/19
3-Month
2.65 +8.30%
on 06/10/19
3.88 -26.03%
on 03/19/19
-0.88 (-23.47%)
since 03/18/19
52-Week
2.65 +8.30%
on 06/10/19
11.65 -75.36%
on 06/20/18
-1.08 (-27.34%)
since 06/18/18

Most Recent Stories

More News
Caladrius Biosciences Reports 2019 First Quarter Financial Results and Provides Corporate Update

All enrolling clinical programs advancing with top-line data expected in late 2019 and during 1H2020 for CLBS14-CMD and CLBS12, respectively

CLBS : 2.86 (-1.38%)
Caladrius Biosciences to Participate at the Upcoming May Conferences

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have...

CLBS : 2.86 (-1.38%)
Caladrius Biosciences to Host 2019 First Quarter Financial Results Conference Call on Thursday, May 9, 2019 at 4:30 p.m. Eastern Time

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have...

CLBS : 2.86 (-1.38%)
New Research: Key Drivers of Growth for Sunworks, Murphy, WNS (Holdings), Caladrius Biosciences, Full House Resorts, and Kewaunee Scientific -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Sunworks, Inc. (NASDAQ:SUNW),...

MUSA : 85.60 (+1.40%)
CLBS : 2.86 (-1.38%)
FLL : 2.04 (unch)
SUNW : 0.72 (unch)
WNS : 59.13 (+0.42%)
KEQU : 22.00 (+0.46%)
Caladrius Biosciences to Participate in Upcoming Conferences

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have...

CLBS : 2.86 (-1.38%)
Caladrius Biosciences Reports 2018 Fourth Quarter and Year End Financial Results

CLBS : 2.86 (-1.38%)
Caladrius Biosciences announces Purchase Agreement with Lincoln Park Capital for up to $26 million

BASKING RIDGE, NJ / ACCESSWIRE / March 14, 2019 / Caladrius Biosciences, Inc. (NASDAQ: CLBS) (''Caladrius'' or the ''Company''), a late-stage therapeutics development biopharmaceutical company committed...

CLBS : 2.86 (-1.38%)
Caladrius Biosciences to Host 2018 Fourth Quarter and Year End Financial Results Conference Call on Thursday, March 14, 2019 at 4:30 p.m. Eastern Time

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have...

CLBS : 2.86 (-1.38%)
Caladrius Biosciences to Present at the Alliance for Regenerative Medicine 7th Annual Cell & Gene Therapy Investor Day

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have...

CLBS : 2.86 (-1.38%)
Caladrius Biosciences Reports Top-Line Data for the Phase 2a Sanford Project: T-Rex Trial of CLBS03 for Recent Onset Type 1 Diabetes

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a late-stage therapeutics development biopharmaceutical company with multiple development programs targeting select cardiovascular...

CLBS : 2.86 (-1.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Soft. Long term indicators fully support a continuation of the trend.

See More Share

Trade CLBS with:

Business Summary

Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve...

See More

Key Turning Points

2nd Resistance Point 3.01
1st Resistance Point 2.95
Last Price 2.86
1st Support Level 2.79
2nd Support Level 2.69

See More

52-Week High 11.65
Fibonacci 61.8% 8.21
Fibonacci 50% 7.15
Fibonacci 38.2% 6.09
Last Price 2.86
52-Week Low 2.65

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar